Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Common buspirone (Buspar) side effects include dizziness, lightheadedness, headache, nausea, nervousness, restlessness, drowsiness, and blurred vision, with dizziness being the most frequently reported. Most of these early effects are mild and tend to ease within the first one to two weeks as your body adjusts, while the full anti-anxiety benefit often takes two to four weeks to build. Timing varies by dose, how quickly it was increased, and other medications you take, and a few reactions such as chest pain, fainting, uncontrolled muscle movements, or severe agitation need prompt medical attention rather than waiting them out. There are several important factors to consider, including when a side effect signals something other than medication adjustment, so review the complete details below before deciding to wait or call your prescriber.
If you are unsure whether what you feel is a settling side effect, an anxiety symptom, or a separate issue, a free, instant, online symptom check can help you sort through your specific symptoms in minutes and point you toward the right next step.
Last reviewed for medical accuracy: 10/01/2025
Buspar (buspirone) is a prescription medication commonly used to treat generalized anxiety disorder (GAD). Unlike benzodiazepines, it does not carry a high risk of dependence and is often chosen for long-term management of anxiety symptoms. Understanding the side effects of Buspar—and how long they’re likely to last—can help you stick with your treatment plan and talk confidently with your doctor.
Most people tolerate Buspar well, but mild side effects can occur, especially during the first few days of treatment. These typically improve as your body adjusts.
• Dizziness or lightheadedness
• Headache
• Nausea or upset stomach
• Nervousness or excitement
• Dry mouth
• Fatigue or drowsiness
• Blurred vision
• Difficulty sleeping (insomnia)
According to the U.S. Food and Drug Administration (FDA) prescribing information and clinical trials published in peer-reviewed journals, up to 20% of patients experience one or more of these effects.
In general, most mild to moderate side effects peak within the first week and gradually subside over 2–4 weeks as your body adapts to buspirone.
• Week 1: Side effects often most noticeable.
• Weeks 2–4: Many patients report significant improvement in dizziness, nausea, headache and fatigue.
• After Week 4: If side effects persist or worsen, discuss adjustments or alternatives with your doctor.
Staying hydrated, taking Buspar with food, and maintaining a regular sleep schedule can help reduce discomfort.
While rare, Buspar can cause more severe reactions that require prompt medical attention. Always watch for:
• Chest pain or tightness
• Rapid or irregular heartbeat
• Shortness of breath
• Severe dizziness or fainting
• Confusion or hallucinations
• Signs of serotonin syndrome (more likely if combined with other serotonergic drugs):
– Agitation or restlessness
– High fever, sweating
– Muscle stiffness, tremor
– Rapid heart rate, dilated pupils
– Diarrhea
Buspirone’s risk of serotonin syndrome is low compared to SSRIs, but caution is warranted if you’re taking other antidepressants, migraine medications (triptans), or supplements like St. John’s wort.
Immediate medical care is needed for hives, swelling of the face/lips/tongue, or severe skin rash. These reactions are extremely rare but potentially life-threatening.
Always consult your healthcare provider if you experience:
• Side effects that don’t improve after 4 weeks
• Any serious or life-threatening symptoms listed above
• New or worsening depression, suicidal thoughts or behavior
• Interactions with other medications you’re starting or stopping
For non-urgent questions or to get an early sense of whether your symptoms warrant a visit, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide if you should seek immediate care or discuss adjustments with your doctor.
Remember that untreated anxiety carries its own risks—poor sleep, impaired concentration, physical symptoms like high blood pressure, and reduced quality of life. Buspar’s overall safety profile makes it a reasonable choice for many people seeking relief from chronic anxiety. Your doctor will weigh:
• Severity and impact of your anxiety
• Other medical conditions and current medications
• Your personal tolerance for potential side effects
Buspirone (Buspar) can be an effective, non-habit-forming option for managing anxiety. Most side effects are mild, emerge early, and fade within a few weeks. Staying informed and communicating openly with your healthcare provider ensures you get the maximum benefit with minimal discomfort.
If you notice any serious or life-threatening reactions—or if common side effects persist beyond a month—please speak to a doctor right away. Your health and safety come first.
(References)
* Hilleman DE, Mohiuddin SM, Del Core MG, Sketch MH Sr. Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med. 1992 Feb;152(2):350-2. PMID: 1739365.
* Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21(3):124-30. doi: 10.1159/000118565. PMID: 2615929.
* Rzewuska M, Sobucka K. [Buspirone in the treatment of Generalized Anxiety Disorders]. Psychiatr Pol. 1993 Sep-Oct;27(5):545-61. PMID: 8255947.
* Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. doi: 10.2165/00003088-200038010-00003. PMID: 10668858.
* Pike E, Stoops WW, Rush CR. Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine. Pharmacol Biochem Behav. 2016 Nov-Dec;150-151:87-93. doi: 10.1016/j.pbb.2016.09.009. Epub 2016 Sep 30. PMID: 27697553; PMCID: PMC5145756.
* Tachere RO, Modirrousta M. Beyond anxiety and agitation: A clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296-298. PMID: 28472575.
* Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2019 Jan 28;1(1):CD008940. doi: 10.1002/14651858.CD008940.pub3. Epub 2019 Jan 28. PMID: 30687936; PMCID: PMC6360924.
* Drugs for depression. Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200. doi: 10.58347/tml.2023.1691a. PMID: 38133585.
* Barakeh D, Mdaihly H, Karaoui LR. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. Ann Pharmacother. 2025 Feb;59(2):148-161. doi: 10.1177/10600280241253273. Epub 2024 May 20. PMID: 38767282.
* DeBattista C, Schatzberg AF. The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. doi: 10.64719/pb.4493. PMID: 38993656; PMCID: PMC11235576.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.